The two source records do not appear to describe the same corporate event. One says BridgeBio Pharma, Inc. (Nasdaq: BBIO) approved restricted stock unit awards covering 66,705 shares for 56 new employees on Aug. 8, 2026 under Nasdaq Listing Rule 5635(c)(4). The other says BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) granted two July 2026 hires non-qualified stock options covering 65,350 shares on Aug. 10, 2026 under its 2025 Inducement Plan at an exercise price of $9.28 per share, also under Nasdaq Listing Rule 5635(c)(4).